Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Work
Year: 2012
Type: article
Source: The Lancet Oncology
Institutions USP Institut Universitari Dexeus, Institut Català d'Ornitologia, Institut Català d'Oncologia, Centre François Baclesse, Hôpital Dupuytren +44 more
Cites: 23
Cited by: 5,234
Related to: 10
FWCI: 383.2
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: closed